Subscribe
Tualek Photography / Shutterstock.com
6 March 2025NewsAmericasMarisa Woutersen

Regeneron edges closer to Eylea market exclusivity amid biosimilar threats

New York biotech scores win as Fed Circ upholds preliminary injunction against Celltrion's biosimilar launch | Ruling follows intense scrutiny during Fed Circ oral arguments | Decision follows similar rulings against Samsung Bioepis and Formycon.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Courtroom report: Regeneron’s $6bn biosimilar battle against Mylan
13 February 2025   The company’s Eylea treatment patent faced intense scrutiny as the US Federal Circuit heard Williams & Connolly, RMMS Legal, and McGuireWoods argue over criticality, stability, and validity.
Americas
Regeneron holds off copies of $6bn eye treatment
4 February 2025   Federal Circuit upholds preliminary injunctions blocking highly similar versions of Eylea | Samsung Biopeis and Formycon failed to convince that the patent-in-suit was invalid.


Editor's picks

Americas
LSPN finalists revealed for first-ever US awards
3 March 2025

Editor's picks

Americas
LSPN finalists revealed for first-ever US awards
3 March 2025
Americas
Fed Circ ruling on Wuhan import ban shakes up economic prong analysis
11 February 2025
Americas
Regeneron holds off copies of $6bn eye treatment
4 February 2025
Careers
Bristows appoints Irish patent attorney to boost UPC representation
4 February 2025
Americas
New national rankings recognise top US patent firms and lawyers
4 February 2025
Europe
UK court upholds EU SPC precedent, rejecting MSD’s appeal
30 January 2025

More on this story

Americas
Courtroom report: Regeneron’s $6bn biosimilar battle against Mylan
13 February 2025   The company’s Eylea treatment patent faced intense scrutiny as the US Federal Circuit heard Williams & Connolly, RMMS Legal, and McGuireWoods argue over criticality, stability, and validity.
Americas
Regeneron holds off copies of $6bn eye treatment
4 February 2025   Federal Circuit upholds preliminary injunctions blocking highly similar versions of Eylea | Samsung Biopeis and Formycon failed to convince that the patent-in-suit was invalid.

More on this story

Americas
Courtroom report: Regeneron’s $6bn biosimilar battle against Mylan
13 February 2025   The company’s Eylea treatment patent faced intense scrutiny as the US Federal Circuit heard Williams & Connolly, RMMS Legal, and McGuireWoods argue over criticality, stability, and validity.
Americas
Regeneron holds off copies of $6bn eye treatment
4 February 2025   Federal Circuit upholds preliminary injunctions blocking highly similar versions of Eylea | Samsung Biopeis and Formycon failed to convince that the patent-in-suit was invalid.

More features

Teva can’t revive Orange book inhaler battle at Fed Circ
Jones Day adds experienced patent litigators from Weil
WIPR Leaders revamps selection process for 2025 edition
La Prairie accused of stealing caviar biotech for luxury skincare line
LSPN finalists revealed for first-ever US awards
Amy Candido to head IP litigation team at Simpson Thacher
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
Abbott v Sibio: A game-changer for UPC tech disputes